- Tags: retina
Business
iCare and MediWhale partner on AI-based CVD retinal imaging
Strategic collaboration would integrate iCare’s DRSplus fundus imaging system with the autonomous Mr. Noon CVD software to predict patients’ CVD risk.
Research
Seasonal variations play major role in CSC development
Observed increased incidence of CSC in spring and autumn provide potential insights into the disease’s pathogenesis.
Research
Reducing chronic inflammation minimizes AMD-linked vision loss
Mouse model demonstrates role of NLRP3 in AMD pathology and highlights potential therapeutic approaches.
Research
Researchers develop clinical decision tool for GA treatment
Atrophy Advisor could help clinicians determine the optimal therapeutic approach for GA patients.
Research
First real-world data shows early promise of high-dose aflibercept for wet AMD
Eight-week findings from the SPECTRUM observational study indicate a safety profile consistent with prior evaluations.
Research
Study demonstrates accuracy of new platform for comparing AI-based DR screening systems
New testing platform allows for comparison of effectiveness and fairness in commercial AI systems.
Pipeline
FDA grants Orphan Drug designation to BlueRock's RP cell therapy
Marks second designation for OpCT-001; includes tax credits for qualified clinical testing and, if approved, 7 years of U.S. market exclusivity.
Pipeline
BioAge Labs expands into DME clinical program for oral inhibitor asset
Preclinical evidence on NLRP3 inhibitor BGE-102 shows potential for therapeutic retinal exposure, with an initial POC trial to kick off later this year.
Research
Could high HDL levels lead to lower DR risk?
Study emphasizes importance of monitoring HDL levels in patients with diabetic retinopathy.
Research
GLP-1 use may lower long-term DME, DR risk
Study highlights protective effect of GLP-1 RAs against ocular complications of diabetes and disparities for racialized patients
Pipeline
Complement Therapeutics secures Fast Track Designation for lead GA therapy
AAV-based CTx001 modulates multiple pathways of the complement system when delivered as a one-time, subretinal injection.
Pipeline
Aviceda releases phase 2b topline data on AVD-104 for GA
Latest SIGLEC trial results show both dosing arms with 31% to 38% less lesion growth than prior trials; phase 3 plans are underway.
Events
Registration opens for the American Retina Forum with Eyes On Eyecare 2026
First-time virtual collaboration invites the next generation of retinal specialists to hear from leading clinical experts and claim CME credits.
Pipeline
FDA rejects Outlook Therapeutics' third BLA submission of bevacizumab for wet AMD
Agency cites need for confirmatory evidence of efficacy as reason for latest CRL; ONS-5010 is already approved in the EU and UK as LYTENAVA.
Research
Does YAG capsulotomy increase DR risk?
Study highlights need for close monitoring of NPDR patients after posterior capsule opacification treatment.
Research
Could DR screenings benefit CVD detection?
Study explores potential of unexpected early advantages for patients with type 2 diabetes mellitus during routine eye exams.
Research
Clinicians are under-utilizing this AI-based DR screening system
EyeArt system demonstrates high diagnostic accuracy in detecting DR, though obstacles remain for real-world implementation.
Research
Study links DME to systemic microvascular complications in diabetes
Analysis highlights the interconnected relationship between DR, neuropathy, and nephropathy in T2DM.
Pipeline
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD
Company expects to submit package in Q1 2026, following the anticipated release of positive 1-year data from the phase 3 SOL-1 trial.
Pipeline